Navigation Links
AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimer's Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
Date:10/20/2009

VIENNA, Austria, October 20 /PRNewswire/ -- AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals.

All 48 patients treated in these studies were given four vaccinations which were well tolerated and no serious side effects associated with the vaccine candidates were observed.

The results demonstrate the potential value of the AFFITOME(R) technology, which forms the platform for both of these vaccines and could result in a generation of highly specific vaccines. While analysing the clinical outcome in detail the company, together with GSK Biologicals is progressing to the next development stage. AFFiRiS AG is also using AFFITOME(R) technology to develop vaccines for Parkinson's disease, atherosclerosis and four other indications.

Affinity to Success

Commenting on the results, AFFiRiS' CEO, Dr. Walter Schmidt, said: "This initial demonstration of safety and tolerability is an outstanding milestone in our joint efforts with GSK Biologicals to develop a therapeutic Alzheimer's vaccination. However, the results also highlight the potential capability of our AFFITOME(R) technology, which forms the basis for the two vaccine candidates. This technology is also the platform for our six other vaccine programmes, including Parkinson's and atherosclerosis currently under development. The results not only represent an important milestone in the development of our Alzheimer's vaccination but also confirm our basic strategy. We will be investing all of this milestone payment in our research and development projects."

In October 2008 AFFiRiS concluded a licensing agreement with GSK Biologicals on jointly developing the Alzheimer's vaccin
'/>"/>

SOURCE AFFiRis AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AFFiRiS Begins Development of a Parkinsons Vaccine
2. AFFiRiS: Milestone Reached in Clinical Trial of Alzheimers Vaccine
3. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
4. Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
5. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Encouraging Gene Therapy Results in Genetic Form of Blindness
7. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
8. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
9. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
10. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
11. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... a first-in-human Phase 1 clinical trial of APD597, a ... the glucose-dependent insulinotropic receptor (GDIR) for the treatment of ... Arena and has the potential to stimulate insulin release ...
... Corporation of North,America today announced that the U.S. ... disodium) Injection, an intravenous,sedative-hypnotic agent for monitored anesthesia ... therapeutic procedures. , ... LUSEDRA be used only by persons,trained in the ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 3Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 4FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 2FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 4
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... sex for one year will be allowed to donate blood in ... a 31-year ban on donations from men who have sex with ... intention to release a new draft guidance in early 2015 that ... The FDA is changing its policy based on data from ...
(Date:12/24/2014)... News) -- A new, injectable weight-loss drug has been ... The agency on Tuesday approved Saxenda (liraglutide) for adults ... and have at least one weight-related health condition, such ... cholesterol. Patients taking the drug, made by Novo ... regularly, the FDA noted. "Obesity is a public ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... Teens are more likely to start smoking or drinking ... disorder (ADHD) or conduct disorder, new research suggests. ... about the risk of substance use as [these] children ... director at Cincinnati Pediatric Research Group, which is part ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Gluten, a ... on those who have an intolerance to gluten, causing ... gas, bloating, migraine headaches, joint pain and fatigue. For ... diet plans that deliver safe and fast weight ... that trigger a gluten allergy reaction. These gluten free ...
(Date:12/24/2014)... 24, 2014 Dr. Svetlana Gomer, MGS ... the nation gathered with US Marines on November 14, ... funds for the Toys for Tots Literacy Program. ... of new books and audio books for the Toys ... children this Christmas. It represents another major strike in ...
Breaking Medicine News(10 mins):Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... The Johns Hopkins Bloomberg School of Public Health has awarded ... efforts to reduce polio globally as well as his work ... Democratic Republic of Congo. Mutombo will be presented with the ... Health in Baltimore, Md., on April 13. "Mr. Mutombo ...
... News) -- In most people, plaque formation in arteries occurs ... according to a new study. Researchers at the Karolinska ... surgery to remove plaque buildup in arteries in their neck. ... than the patients, who were on average 68 years old ...
... available in Spanish and French . ... a conflict arises within the couple. Conversely, it is men ... cause conflicts more frequently. This is the conclusion described ... prepared by professors from the Department of Social Psychology ...
... pregnant women, high induction and first-cesarean delivery rates do not ... published in the April issue of The Journal of ... of intervention at delivery whether high, low, or in ... new babies brings into question the skyrocketing number of both ...
... IL (April 13, 2011 ) This week at ... about dietary cholesterol intake and cardiovascular disease risk were ... variety of poster presentations. Experts from leading institutions discussed ... its association with heart disease risk, dispelling some commonly ...
... Children were the victims in more than half of the ... between 1997 and 2009, according to a new study by ... to prevent injury from the pressurized and often harsh chemical ... 0 to 4, were the most likely to be hurt ...
Cached Medicine News:Health News:Artery Plaque Forms in Short Time Span, Scientists Say 2Health News:Women have more intense emotions than men when conflict arises within the couple 2Health News:More interventions at delivery not linked to healthier newborns 2Health News:More interventions at delivery not linked to healthier newborns 3Health News:Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk 2Health News:Children victims of most eye injuries from aerosols 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: